Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BBI-825

Small molecule · Inhibitor of ribonucleotide reductase · developed by Boundless Bio

Phase 1 Most advanced trial (none active)
BOLD Developer
1 Registered trials

What is BBI-825?

BBI-825 is an orally available small molecule that selectively inhibits ribonucleotide reductase, the enzyme that converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates for DNA synthesis. By reducing the deoxyribonucleotide pool, it disrupts DNA synthesis and cell cycle progression. It is studied in multiple solid tumors, including triple negative breast cancer, ovarian, endometrial, head and neck, and small cell lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
ribonucleotide reductase
Mechanism
Inhibitor of ribonucleotide reductase
Pathways
DNA synthesis, dNTP pool depletion, extrachromosomal DNA assembly and repair, cell cycle arrest
Therapy area
Oncology
Developer
Boundless Bio, Inc. (BOLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05827614 Phase 1 Triple Negative Breast Cancer (TNBC) Terminated BOLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anogenital CancerCervical Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)ER+ Breast CancerHead and Neck (HNSCC)High Grade Endometrial CarcinomaHigh Grade Serous Ovarian CarcinomaLeiomyosarcoma (LMS)Pancreatic Cancer MetastaticSmall Cell Lung CancerTriple Negative Breast Cancer (TNBC)Undifferentiated Pleomorphic Sarcoma (UPS)

More from Boundless Bio

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLD page.

Follow BOLD, the company behind BBI-825

See BOLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.